Pacific International Journal, Vol. 8(2); 2025
ISSN (Print) 2663-8991, ISSN (Online) 2616-4825[1]
DOI:10.55014/pij.v8i2.794
https://rclss.com/index.php/pij

Clinical Application and Mechanistic Investigation of GLP-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome

Yan Liu[1] Jing Fan[*] Le Jiang[2]

[1]Inner Mongolia Autonomous Region People's Hospital, Hohhot, China
[*(Corresponding Author)]Hohhot International Travel Health Care Center(Hohhot Customs Out-patient Department)

Email: 376650095@qq.com; 360234268@qq.com; jiangle1989@163.com

Abstract: Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance, leading to significant impairment of reproductive health and overall quality of life. Recent attention has been directed toward glucagon-like peptide-1 (GLP-1) receptor agonists, a novel class of metabolic modulators, due to their potential therapeutic effects in improving insulin resistance and regulating metabolic pathways. This study aims to evaluate the clinical efficacy and underlying mechanisms of GLP-1 receptor agonists in the management of PCOS, synthesizing findings from randomized controlled trials (RCTs) and real-world studies. Our analysis demonstrates that GLP-1 receptor agonists effectively reduce body weight, alleviate insulin resistance, and enhance reproductive function in PCOS patients. These agents also decrease androgen levels, promote ovulation, and increase pregnancy rates. Mechanistic investigations suggest that GLP-1 receptor agonists exert comprehensive metabolic regulatory effects by modulating insulin signaling pathways, enhancing central appetite control, and reducing inflammatory responses. Furthermore, GLP-1 receptor agonists exhibit favorable safety profiles, with mild gastrointestinal discomfort as the primary adverse effect, and high patient adherence. In conclusion, GLP-1 receptor agonists offer a promising novel therapeutic approach for PCOS, particularly in addressing metabolic disturbances and improving reproductive outcomes. Future multicenter, large-scale RCTs are warranted to refine clinical protocols and further elucidate their mechanisms, thereby providing more tailored treatment options for PCOS patients.

Keywords: GLP-1 receptor agonists; polycystic ovary syndrome; insulin resistance; reproductive function; metabolic regulation

1. Introduction

1.1 Research Background

Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders affecting women of reproductive age, with a prevalence rate ranging from 5% to 10%. The cardinal features of PCOS include hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. These symptoms are often compounded by obesity, insulin resistance (IR), and metabolic syndrome. Such metabolic disturbances not only impair reproductive health but also predispose patients to increased risks of cardiovascular disease, type 2 diabetes, and endometrial cancer.

In recent years, GLP-1 receptor agonists, a novel class of metabolic modulators, have shown significant clinical benefits in the treatment of diabetes and obesity. These agonists regulate appetite, delay gastric emptying, enhance insulin secretion, and improve insulin sensitivity through the mimicry of incretin action. Given that insulin resistance is a central pathological feature of PCOS, the therapeutic potential of GLP-1 receptor agonists in managing this condition has garnered considerable attention.

1.2 Research Objectives

The primary objective of this study is to evaluate the clinical applicability of GLP-1 receptor agonists in the management of PCOS, focusing on their impact on metabolic and reproductive functions. The specific goals include:

- To assess the effects of GLP-1 receptor agonists on body weight, insulin resistance, and reproductive function in patients with PCOS.
- To elucidate the mechanisms by which GLP-1 receptor agonists improve insulin resistance and regulate reproductive endocrinology in PCOS.
- To evaluate the efficacy and safety of GLP-1 receptor agonists, providing a basis for their clinical application in PCOS management.

1.3 Significance of the Study

The introduction of GLP-1 receptor agonists as a potential treatment for PCOS carries significant clinical implications. PCOS patients often exhibit poor responses to conventional therapies due to coexisting obesity and insulin resistance. Given the growing prevalence of metabolic diseases, GLP-1 receptor agonists offer a promising new therapeutic option for this patient population. This study aims to provide both theoretical insights and practical guidance on the use of GLP-1 receptor agonists in non-diabetic metabolic disorders, such as PCOS.

[Received 11 February 2025; Accepted 12 April 2025; Published (online) 20, April, 2025]

2. Pharmacological Basis of GLP-1 Receptor Agonists

2.1 Mechanisms of Action of GLP-1 Receptor Agonists

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells. It exerts multiple physiological effects by binding to the GLP-1 receptor, which is widely distributed across various tissues, including the pancreas, brain, and gastrointestinal tract. The primary mechanisms through which GLP-1 receptor agonists act include:

2.1.1 Modulation of Appetite and Satiety GLP-1 acts on the hypothalamic appetite center, inhibiting hunger and increasing satiety, thereby reducing food intake. This not only assists in weight management but also contributes to improved insulin sensitivity by reducing caloric intake.

2.1.2 Enhancement of Insulin Secretion and Sensitivity GLP-1 receptor agonists stimulate insulin secretion from pancreatic β-cells in a glucose-dependent manner, while also inhibiting glucagon release. This dual action helps lower blood glucose levels without inducing hypoglycemia. Additionally, GLP-1 improves peripheral tissue insulin sensitivity, likely through activation of the AMP-activated protein kinase (AMPK) pathway.

2.1.3 Delayed Gastric Emptying GLP-1 receptor agonists slow gastric emptying by acting on the smooth muscles of the gastrointestinal tract. This mechanism helps reduce the postprandial rise in blood glucose and enhances satiety, contributing to reduced food intake.

2.2 Metabolic Regulatory Effects of GLP-1 Receptor Agonists

2.2.1 Weight Reduction GLP-1 receptor agonists induce weight loss through multi-target effects, including appetite suppression, delayed gastric emptying, and enhanced insulin sensitivity. The efficacy of GLP-1/GIP dual-target agonists, such as tirzepatide, has been demonstrated in clinical trials, showing up to 21% weight loss in patients with metabolic disorders. Ultra-long-acting formulations like Eglucagon α, with a half-life of over 200 hours, also show promising weight loss outcomes while improving patient compliance by reducing the frequency of dosing.

2.2.2 Improvement in Lipid Metabolism GLP-1 receptor agonists have been shown to improve lipid profiles, including a reduction in low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), while enhancing high-density lipoprotein cholesterol (HDL-C) levels. These effects contribute to the improvement of overall metabolic health and a reduction in cardiovascular risk.

2.2.3 Cardiovascular Protection GLP-1 receptor agonists have been associated with significant cardiovascular benefits. They improve insulin resistance, reduce body weight, and lower blood pressure, triglycerides, and cholesterol levels. Furthermore, they possess anti-inflammatory and antioxidant properties that help mitigate oxidative stress, thereby reducing the risk of cardiovascular diseases. Additionally, these agents offer renal protection by inhibiting inflammation and improving metabolic disorders, which is particularly beneficial in managing diabetic nephropathy.

2.2.1 Modulation of Appetite and Satiety

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L cells, playing a pivotal role in regulating glucose homeostasis and appetite. GLP-1 receptor agonists (GLP-1RAs) replicate the physiological actions of endogenous GLP-1, thereby eliciting a range of metabolic effects. A key mechanism by which GLP-1RAs influence appetite and satiety is through their interaction with the hypothalamic appetite center. By binding to GLP-1 receptors within the hypothalamus, these agonists suppress appetite and enhance feelings of fullness, thereby reducing food intake.

This anorexigenic effect is particularly beneficial for individuals with obesity and insulin resistance—common comorbidities in polycystic ovary syndrome (PCOS). Reduced caloric intake not only facilitates weight management but also improves insulin sensitivity. By decreasing overall energy consumption, GLP-1RAs help normalize glucose levels and mitigate the risk of hyperglycemia.

2.2.2 Enhancement of Insulin Secretion and Sensitivity

GLP-1RAs promote insulin secretion from pancreatic β-cells in a glucose-dependent manner, which means their effect is more pronounced when blood glucose levels are elevated. This action helps attenuate postprandial glucose spikes and maintain stable blood glucose levels. Moreover, GLP-1RAs suppress glucagon secretion, a hormone that stimulates hepatic glucose production. By inhibiting glucagon release, GLP-1RAs further contribute to lowering blood glucose levels. The combined effects of enhanced insulin secretion and glucagon suppression lead to more balanced glucose metabolism, which is particularly beneficial for patients suffering from insulin resistance. Given that insulin resistance is a hallmark of PCOS and a major contributor to hyperandrogenism and reproductive dysfunction, the improvement in insulin sensitivity offered by GLP-1RAs can address critical metabolic abnormalities and improve overall metabolic health in this population.

2.2.3 Delayed Gastric Emptying

An additional mechanism through which GLP-1RAs exert their effects is by modulating gastric emptying. GLP-1RAs slow gastric emptying by acting on the smooth muscle of the gastrointestinal tract, thus delaying the rate at which food passes from the stomach into the small intestine. This delay in gastric emptying reduces the rapid increase in postprandial blood glucose and promotes a greater sense of fullness, further contributing to weight loss.

The delayed gastric emptying effect is particularly valuable for managing obesity, as it reduces overall caloric intake and enhances satiety. This mechanism, in combination with the anorexigenic effects of GLP-1RAs, makes them highly effective for weight management in PCOS patients.

2.2.4 Metabolic Regulatory Effects of GLP-1 Receptor Agonists

2.2.4.1 Weight Loss Effects

GLP-1RAs have demonstrated substantial weight loss effects in clinical trials, making them valuable tools for addressing obesity, a prevalent comorbidity in PCOS. The weight loss observed with GLP-1RAs is attributed to their multi-faceted mechanisms of action, which include appetite suppression, improved insulin sensitivity, and delayed gastric emptying.

Recent advancements in GLP-1 receptor agonist formulations have led to the development of dual-target agents, such as tirzepatide, which combine the effects of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). These dual-acting agents have shown even more pronounced weight loss efficacy, with some studies reporting up to a 21% reduction in body weight in phase III clinical trials.

2.2.4.2 Improvement in Lipid Metabolism

Beyond their effects on weight, GLP-1RAs have been shown to positively influence lipid metabolism, which further enhances their therapeutic potential in PCOS. These agents reduce low-density lipoprotein cholesterol (LDL-C) levels by improving insulin sensitivity and decreasing hepatic cholesterol synthesis. They also lower triglyceride (TG) levels by inhibiting hepatic fat synthesis and secretion, while simultaneously increasing high-density lipoprotein cholesterol (HDL-C) levels through improvements in overall metabolic status.

Improving lipid profiles is especially important in PCOS, where dyslipidemia is a common metabolic disturbance. By addressing both weight and lipid metabolism, GLP-1RAs offer a comprehensive approach to managing the metabolic complications associated with PCOS.

2.2.4.3 Cardiovascular Protection

In addition to their metabolic benefits, GLP-1RAs have been demonstrated to offer cardiovascular protection—an important consideration in the management of PCOS. These agents improve insulin resistance and reduce weight, both of which are recognized risk factors for cardiovascular disease. Furthermore, GLP-1RAs have been shown to lower blood pressure and improve lipid profiles, thus further reducing cardiovascular risk.

The anti-inflammatory and antioxidant properties of GLP-1RAs contribute to their cardiovascular benefits. By inhibiting inflammatory responses and reducing oxidative stress, GLP-1RAs help protect against the development of atherosclerosis and other cardiovascular complications, which are of particular concern in patients with PCOS.

2.2.4.4 Renal Protection

Finally, GLP-1RAs exhibit protective effects on renal function, a significant consideration for PCOS patients, who are at heightened risk for developing diabetic nephropathy. These agents enhance metabolic control by reducing inflammatory responses and improving insulin sensitivity, thereby decreasing the likelihood of renal damage. This nephroprotective effect further underscores the potential of GLP-1RAs as part of a comprehensive approach to managing PCOS and its associated complications.

2.3 Clinical Application of GLP-1 Receptor Agonists

GLP-1 receptor agonists have been widely established in the treatment of type 2 diabetes mellitus (T2DM), with extensive evidence from randomized controlled trials (RCTs) and real-world studies confirming their efficacy in glycemic control, weight loss, and cardiovascular protection. Moreover, their role in managing obesity has gained significant attention, with drugs like semaglutide and liraglutide yielding favorable weight loss outcomes. However, the application of GLP-1 receptor agonists in non-diabetic metabolic disorders, particularly in the treatment of polycystic ovary syndrome (PCOS), remains in the exploratory phase.

3. Clinical Application of GLP-1 Receptor Agonists in PCOS Treatment

3.1 Clinical Characteristics and Current Treatment of PCOS

3.1.1 Clinical Characteristics of PCOS

Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder characterized by:

- Menstrual irregularities: Manifesting as oligomenorrhea, amenorrhea, or irregular bleeding.
- Hyperandrogenism: Clinically presenting as hirsutism, acne, and alopecia.
- Polycystic ovarian morphology: Identified through ultrasound as multiple cysts within the ovaries.
- Metabolic disturbances: Including obesity, insulin resistance (IR), and dyslipidemia.

3.1.2 Current Treatment of PCOS

The primary objectives in the treatment of PCOS are to alleviate symptoms, correct metabolic disturbances, restore reproductive function, and enhance quality of life. Traditional therapeutic approaches include:

- Lifestyle interventions: Weight management is critical, especially for obese PCOS patients, with studies indicating that a 5-10% weight reduction significantly improves reproductive function and metabolic health. For non-obese patients, emphasis is placed on body composition, with resistance training used to increase skeletal muscle mass and improve insulin sensitivity.
- Pharmacological treatments: Oral contraceptives (COCs) are commonly prescribed to regulate menstrual cycles and alleviate androgenic symptoms. Insulin sensitizers, such as metformin, are frequently used to manage insulin resistance, with thiazolidinediones (e.g., pioglitazone) serving as alternatives or adjuncts. Ovulation induction agents are prescribed for infertility.
- Menstrual regulation: Progestins are utilized cyclically for women with irregular cycles, and estrogen-progestin sequential therapy is used for those with insufficient endogenous estrogen.
- Management of androgenic symptoms: For patients experiencing significant androgenic manifestations, COCs or anti-androgen medications are recommended.

Despite the availability of these traditional treatments, their efficacy in addressing insulin resistance and promoting weight loss remains suboptimal, and long-term use may result in side effects. As such, the exploration of new treatment strategies, including GLP-1 receptor agonists, is crucial for improving patient outcomes in PCOS.

3.2 Clinical Studies on the Use of GLP-1 Receptor Agonists in PCOS Treatment

Recent studies have explored the clinical efficacy of GLP-1 receptor agonists (GLP-1RAs) in the treatment of polycystic

ovary syndrome (PCOS). These studies include both randomized controlled trials (RCTs) and real-world data.

Randomized Controlled Trials (RCTs)

A randomized controlled trial (RCT) demonstrated that the combination of liraglutide and metformin significantly improved weight, insulin resistance, and reproductive function in women with PCOS. Similarly, another study investigating the effects of semaglutide found an average weight loss of more than 10% in PCOS patients, alongside significant improvements in hyperandrogenemia.

Real-World Studies

Real-world evidence further supports the findings of RCTs, showing that long-term use of GLP-1RAs results in substantial improvements in both metabolic and reproductive health in patients with PCOS. These studies underscore the potential of GLP-1RAs to enhance treatment outcomes in diverse clinical settings.

3.3 Clinical Application of Combined Therapies with GLP-1 Receptor Agonists

Combining GLP-1 receptor agonists with other therapeutic agents has shown synergistic benefits, leading to better clinical outcomes in the treatment of PCOS.

Combination with Metformin

The combination of GLP-1RAs and metformin has proven to be particularly effective in improving insulin resistance and enhancing reproductive function. This combined approach provides a comprehensive strategy for addressing both metabolic and endocrine abnormalities associated with PCOS.

Combination with Other Medications

In addition to metformin, combining GLP-1RAs with other pharmacological agents, such as orlistat, further optimizes weight loss outcomes. Such multi-drug regimens have the potential to maximize therapeutic efficacy in managing obesity and metabolic dysfunction in PCOS patients.

4. Mechanisms of Action of GLP-1 Receptor Agonists in PCOS Treatment

4.1 Mechanisms for Improving Insulin Resistance

GLP-1 receptor agonists exert several beneficial effects on insulin resistance in PCOS patients through multiple molecular and physiological mechanisms:

Regulation of Insulin Signaling Pathways

GLP-1 receptor agonists activate the GLP-1 receptor, which modulates intracellular signaling pathways, notably the AMP-activated protein kinase (AMPK) pathway. AMPK serves as a key metabolic regulator, enhancing glucose uptake in adipose and muscle tissues, thus improving insulin sensitivity. Additionally, GLP-1RAs have been shown to reduce inflammation and oxidative stress, further enhancing insulin signaling and contributing to improved metabolic control.

Regulation of Appetite and Energy Metabolism

By targeting the hypothalamic appetite center, GLP-1RAs reduce appetite and enhance satiety, which leads to reduced food intake. This reduction in caloric consumption directly improves insulin resistance. Furthermore, GLP-1RAs delay gastric emptying, which not only prolongs feelings of fullness but also mitigates postprandial glucose spikes, contributing to better overall glycemic control.

Weight Loss

Weight loss is a critical factor in improving insulin sensitivity, and GLP-1RAs play a significant role in weight reduction through the aforementioned mechanisms. Clinical studies have demonstrated that GLP-1RAs are particularly effective in obese PCOS patients, leading to substantial improvements in insulin resistance and associated metabolic dysfunction.

Improvement of Metabolic Syndrome

In addition to their effects on insulin resistance, GLP-1RAs improve various aspects of metabolic syndrome. These include lowering lipid levels, improving liver function, and optimizing overall metabolic status. These comprehensive effects further alleviate insulin resistance and enhance the metabolic health of PCOS patients.

4.2 Mechanisms for Regulating Reproductive Endocrinology

GLP-1 receptor agonists influence reproductive endocrinology in PCOS patients through several key mechanisms:

Reduction of Androgen Levels

Hyperinsulinemia, a hallmark of PCOS, stimulates the ovaries to produce excess androgens, resulting in hyperandrogenemia. By improving insulin resistance, GLP-1RAs reduce insulin secretion, which in turn decreases the ovarian stimulation that drives androgen synthesis. This is achieved through the following mechanisms:

- Improvement in Insulin Resistance: GLP-1RAs activate the GLP-1 receptor, enhancing insulin sensitivity and reducing the need for insulin secretion.
- Reduction in Androgen Synthesis: By improving insulin sensitivity, GLP-1RAs decrease the ovarian synthesis and secretion of androgens, thus mitigating the symptoms of hyperandrogenemia.

Regulation of the Hypothalamic-Pituitary-Ovarian (H-P-O) Axis

PCOS patients often experience dysfunction in the hypothalamic-pituitary-ovarian (H-P-O) axis, marked by excessive luteinizing hormone (LH) secretion and relatively insufficient follicle-stimulating hormone (FSH) secretion, which impairs normal follicular development and ovulation. GLP-1RAs regulate the H-P-O axis through the following mechanisms:

- Reduction of LH Levels: GLP-1RAs reduce the frequency and intensity of LH secretion, thereby improving the LH/FSH ratio and restoring normal menstrual cycles.
- Improvement of Ovulation Function: By regulating the H-P-O axis, GLP-1RAs help restore normal ovulation, thereby enhancing fertility.

- Regulation of Neuroendocrine Function: GLP-1RAs may also act on the central nervous system, modulating the secretion of gonadotropin-releasing hormone (GnRH) and influencing LH and FSH secretion.

4.3 Anti-inflammatory and Antioxidant Effects

PCOS is commonly associated with a chronic low-grade inflammatory state. GLP-1RAs exhibit both anti-inflammatory and antioxidant properties, which may contribute to their therapeutic effects in PCOS. The key mechanisms involved include:

- Inhibition of Inflammatory Pathways: GLP-1RAs reduce the secretion of pro-inflammatory cytokines, improving the ovarian microenvironment and reducing the systemic inflammatory burden in PCOS patients.
- Enhancement of Antioxidant Defense Mechanisms: These agents increase the activity of antioxidant enzymes, thereby mitigating oxidative stress and contributing to improved metabolic and reproductive function.

5. Efficacy and Safety of GLP-1 Receptor Agonists in the Treatment of PCOS

5.1 Clinical Efficacy Evaluation

GLP-1 receptor agonists (GLP-1RAs) have demonstrated significant clinical efficacy in the treatment of polycystic ovary syndrome (PCOS), with notable improvements in weight management, reproductive function, and metabolic indicators.

5.1.1 Weight Management

GLP-1RAs have shown impressive weight reduction in patients with PCOS, with average weight loss exceeding 10%. This effect is primarily achieved through the following mechanisms:

- Regulation of Appetite and Satiety: GLP-1 activates the hypothalamic appetite center, inhibiting appetite and promoting satiety, thereby reducing caloric intake. This not only aids in weight management but also improves insulin resistance.
- Delaying Gastric Emptying: GLP-1 slows gastric emptying, enhancing satiety and mitigating postprandial blood glucose spikes. This contributes further to weight loss by reducing overall caloric intake.
- Improvement of Insulin Resistance: By modulating insulin signaling pathways, GLP-1RAs indirectly promote fat breakdown and reduce fat storage. Weight loss of 5%-10% can significantly improve menstrual cycles, ovulation, and insulin sensitivity in PCOS patients.

For example, a prospective RCT demonstrated that treatment with exenatide (a GLP-1RA) for 12 weeks resulted in a significantly higher natural pregnancy rate compared to metformin alone.

5.1.2 Reproductive Function Improvement

GLP-1RAs have been shown to improve reproductive function in PCOS patients, with increases in menstrual recovery rates, ovulation rates, and pregnancy rates. The mechanisms involved include:

- Reduction of Androgen Levels: By improving insulin resistance, GLP-1RAs reduce insulin-stimulated androgen secretion, which alleviates hyperandrogenism—a common feature of PCOS.
- Regulation of the Hypothalamic-Pituitary-Ovarian (H-P-O) Axis: GLP-1RAs lower luteinizing hormone (LH) levels, thereby improving the LH/FSH ratio and restoring normal menstrual cycles and ovulation.
- Enhancement of Endometrial Function: In animal models, GLP-1RAs have been shown to reduce endometrial oxidative stress and fibrosis, improving endometrial receptivity. For instance, a study indicated that pre-pregnancy intervention with low-dose liraglutide combined with metformin significantly increased pregnancy rates in obese infertile women undergoing embryo transfer and in vitro fertilization (IVF).

5.1.3 Improvement of Metabolic Indicators

GLP-1RAs significantly enhance metabolic parameters in PCOS patients, including blood glucose levels, lipid profiles, and insulin resistance. The specific effects are as follows:

- Improvement of Blood Glucose: GLP-1RAs stimulate insulin secretion while inhibiting glucagon release, resulting in lower fasting blood glucose levels and improved insulin sensitivity (HOMA-IR).
- Improvement of Lipid Profiles: GLP-1RAs reduce total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) levels, while increasing high-density lipoprotein cholesterol (HDL-C).
- Reduction in Insulin Resistance: Through modulation of insulin signaling pathways and weight reduction, GLP-1RAs significantly improve insulin resistance. A network meta-analysis has demonstrated that GLP-1RAs, when combined with standard therapies, effectively reduce weight, body mass index (BMI), waist circumference, and testosterone levels, while improving insulin resistance.

In summary, GLP-1RAs offer substantial clinical benefits in PCOS treatment by promoting weight loss, enhancing reproductive function, and optimizing metabolic parameters. Future research is needed to refine clinical protocols for their use in PCOS, providing more tailored treatment strategies.

5.2 Safety Evaluation

GLP-1RAs have demonstrated an acceptable safety profile in PCOS treatment, with common adverse reactions and long-term safety data as follows:

5.2.1 Adverse Reactions

The most frequently reported adverse effects of GLP-1RAs in the treatment of PCOS are gastrointestinal (GI) disturbances, including nausea, vomiting, diarrhea, and constipation. These effects are typically mild to moderate and primarily occur during the initial weeks of treatment, with most cases being transient. For instance, in one study, a higher incidence of GI adverse events (such as nausea and vomiting) was observed, although these were generally mild and self-limiting.

In addition, some rare but serious adverse events, such as pancreatitis, intestinal obstruction, and gastroparesis, have been

reported. However, these events are infrequent. Clinically, initiating treatment with a low dose and gradually titrating it upwards can reduce the occurrence of GI side effects.

5.2.2 Long-term Safety

Long-term safety data on GLP-1RAs suggest that these agents have a favorable safety profile, particularly in terms of cardiovascular outcomes. For instance, semaglutide has shown positive cardiovascular safety in long-term studies, with no increased risk of severe hypoglycemia, acute renal failure, acute pancreatitis, retinopathy, or malignancies. A meta-analysis confirmed that GLP-1RAs were effective in weight reduction and improving metabolic parameters, with most adverse events being mild to moderate in nature.

In the context of PCOS, long-term use of GLP-1RAs has demonstrated good tolerability, with no significant adverse events reported. This supports the use of GLP-1RAs not only for short-term management but also for maintaining metabolic and reproductive health improvements over extended periods.

Thus, GLP-1RAs are not only safe and effective in the short term but also suitable for long-term treatment, offering sustained improvements in metabolic and reproductive health for PCOS patients.

5.3 Patient Adherence and Quality of Life Improvement

GLP-1RAs significantly enhance patient adherence and quality of life, with both factors playing a crucial role in treatment success.

5.3.1 Adherence Analysis

The treatment regimen of GLP-1RAs demonstrates high adherence, primarily due to their favorable tolerability profile and convenient dosing schedule. Gastrointestinal adverse reactions are typically mild or moderate and diminish over time, improving patient compliance. Furthermore, long-acting GLP-1RAs (such as semaglutide and tirzepatide), which require only weekly injections, offer greater convenience, further enhancing adherence. For example, one study reported that the adherence rate for GLP-1RA treatment (defined as the proportion of days covered by prescriptions) was 54%, with 35.4% of patients exhibiting good adherence over the course of one year.

5.3.2 Quality of Life Improvement

GLP-1RAs significantly enhance the quality of life for PCOS patients through improvements in both metabolic and reproductive health:

- Weight Loss Effect: GLP-1RAs can lead to weight loss of 5%-15%, which not only improves metabolic health but also significantly boosts self-esteem and quality of life.
- Reproductive Function Improvement: By reducing androgen levels and restoring normal menstrual cycles, GLP-1RAs increase ovulation and pregnancy rates in women with PCOS.
- Cardiovascular Protection: In addition to metabolic benefits, GLP-1RAs offer cardiovascular protection, which further enhances overall health and well-being.

Moreover, the multi-target action of GLP-1RAs (such as GLP-1/GIP dual-target agents) optimizes weight loss and metabolic regulation, further improving the treatment experience for patients.

In conclusion, GLP-1RAs not only improve the metabolic and reproductive outcomes of PCOS patients but also reduce adverse reactions and enhance adherence. Their positive impact on quality of life and their suitability for long-term use make them a promising treatment option for PCOS.

6. Future Research Directions and Prospects

6.1 Future Research Directions for GLP-1 Receptor Agonists in PCOS Treatment

Future research on GLP-1RAs in PCOS treatment will focus on the following key areas:

- Multicenter, Large-Sample RCTs: Further large-scale randomized controlled trials (RCTs) are needed to validate the long-term efficacy and safety of GLP-1RAs in PCOS patients, providing robust data to inform clinical practice.
- Mechanistic Research: An in-depth exploration of the regulatory mechanisms through which GLP-1RAs affect reproductive endocrinology and metabolic processes in PCOS is essential. A deeper understanding of these mechanisms could lead to more targeted and effective therapies.
- Personalized Treatment Approaches: Developing individualized treatment strategies based on genetic and metabolic profiles will allow for more precise interventions, optimizing therapeutic outcomes and minimizing adverse effects.

6.2 Expansion of GLP-1 Receptor Agonists in the Treatment of Metabolic Diseases

The potential applications of GLP-1RAs extend beyond PCOS and include other metabolic disorders, with promising prospects in:

- Non-Alcoholic Steatohepatitis (NASH): GLP-1RAs are being investigated for their efficacy in reducing liver inflammation and fibrosis, offering a potential therapeutic option for NASH.
- Cardiovascular Diseases: Given their effects on weight management and lipid profiles, GLP-1RAs are being explored for primary and secondary cardiovascular disease prevention.

6.3 Conclusions and Prospects

GLP-1RAs have demonstrated significant clinical efficacy and have provided mechanistic breakthroughs in the treatment of PCOS. Ongoing and future research will refine their clinical application strategies, offering more effective and personalized treatment options for PCOS patients. Additionally, the expanding use of GLP-1RAs in metabolic diseases such as NASH and cardiovascular conditions highlights their potential as versatile agents in managing complex metabolic disorders.

Acknowledgement： Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals

of Inner Mongolia Academy of Medical Sciences. Project Number: 2024GLLH0118

References:

[1] Li Minyu, Han Hui. Research Progress on the Therapeutic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome. Chinese Journal of Medicine, 2024.
[2] Yu Tian, Liu Shaohua, Wei Anhua, et al. Pharmacoeconomic Evaluation of Glucagon-Like Peptide-1 Receptor Agonists Combined with Metformin in the Treatment of Type 2 Diabetes Based on a Markov Model. Journal of Pharmacoepidemiology, 2024.
[3] Liao Mingyu, Zhou Ling, Liao Qian, et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists Combined with Metformin on Glucose and Lipid Metabolism and Reproductive Function in Overweight/Obese Polycystic Ovary Syndrome Patients. Chinese Journal of Endocrinology and Metabolism, 2023.
[4] Liu Qiwei, Zhang Junhui, Yang Yuan, Wang Jinjuan. The Role and Mechanism of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Polycystic Ovary Syndrome. Chinese Journal of Tissue Engineering Research, 2024.
[5] Li Danping, Lian Fang, Xiang Shan. New Advances in the Mechanistic Study of Metformin in the Treatment of Polycystic Ovary Syndrome. International Journal of Reproductive Health and Family Planning, 2024.
[6] Wang Feiyu, Jiang Zhen, Liu Yiwei. Correlation Between GLP-1R Gene Polymorphism and the Efficacy of Liraglutide in Patients with Type 2 Diabetes. Shanghai Journal of Medicine, 2021.
[7] Yao Na, Zhao Wenhua, Chen Li, Xu Linxin. Efficacy and Effects on Islet Function of GLP-1 Receptor Agonists Combined with Dapagliflozin in the Treatment of Obese Type 2 Diabetes. Journal of Guizhou Medical University, 2024.
[8] Chen Jiao, Fan Huaying, Zeng Jiuzhi, et al. Clinical Efficacy Observation of Electroacupuncture Cycle Therapy Based on "Ren Meridian Governing the Uterus" Combined with Clomiphene Citrate in the Treatment of Polycystic Ovary Syndrome. Chinese Journal of Traditional Chinese Medicine, 2024.
[9] Aleksandra Jaro, Agata Wikliska, Katarzyna Jastrzbska. The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS. Quality in Sport, 2024.
[10] Sandra Christensen, Katie Robinson, Sara Thomas, Dominique R. Williams. Dietary Intake by Patients Taking GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Narrative Review and Discussion of Research Needs. Obesity Pillars, 2024.